Publication of the activity report and financial information for the first half-year (April – Sept. 2018)

December 3, 2018

Period highlights
In the United States, our partner Teva Pharmaceuticals initiated a Phase III clinical study for an investigational long-acting treatment for schizophrenia. This is the final stage of clinical development before applying for marketing approval. This product formulation (mdc-IRM) is based on our proprietary technology.

Other products in development
•Initiation of non-clinical development activities of a second product in the Central
Nervous System (CNS) in partnership with Teva
• Launch of the first clinical trial (Phase II) in the United States of a product that aims to treat orthopaedic postoperative pain, in partnership with AIC

Enhanced financial visibility
• Cash of €11.4 million in available funds and €4.6 million in non-risky financial assets
• EIB loan: €7.5 million received (a further €12.5 million still available)
• Initial Public Offering: €31.4 million (post-closing event)
• Increase in R&D spending: +23% (compared with the first half of 2017)

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.